🇺🇸 FDA
Patent

US 8217038

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

granted A61PA61P1/16A61P29/00

Quick answer

US patent 8217038 (Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes) held by Jenrin Discovery, LLC expires Mon Jul 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Jenrin Discovery, LLC
Grant date
Tue Jul 10 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61P, A61P1/16, A61P29/00, A61P3/04, A61P3/06